Clinical Trials for Liver and Pancreatic Cancer in Taiwan
|
|
- Collin Peters
- 6 years ago
- Views:
Transcription
1 Japan - Taiwan Joint Symposium on Medical Oncology Session 6 Hepatobiliary and pancreatic cancers Clinical Trials for Liver and Pancreatic Cancer in Taiwan Li-Tzong Chen 1,2 *, Jacqueline Whang-Peng 1,3 journal homepage: 1 National Institute of Cancer Research, National Health Research Institutes 2 Department of Internal Medicine, National Cheng-Kung University Hospital, Tainan 3 Division of Cancer Center, Taipei Medical University Hospital, Taipei Abstract. Although with limited clinical activity, gemcitabine monotherapy is still the standard of care for patients with advanced pancreatic cancer. To improve the therapeutic results of gemcitabine for advanced pancreatic cancer, we firstly had a phase I/II study to determine the maximum tolerated dose of 24-hour infusion of high-dose 5-FU and leucovorin (HDFL) in combination with weekly 800 mg/m 2 of gemcitabine in advanced pancreatic cancer. With the recommended dose of 5-FU, which was determined to be 2000 mg/m 2, the gemcitabine-hdfl regimen could achieve 22% of response rate, 6.9 months of overall survival and acceptable toxicity profile in advanced pancreatic cancer. Then we further incorporated oxaliplatin into the gemcitabine-hdfl regimen. The three drug combination gemcitabine, oxaliplatin plus infusional 5-FU and leucovorin (GOFL regimen) has been shown to be feasible and moderate active in patients with advanced pancreatic cancer, not only as the primary therapy for patients with advanced diseases but also as an inductional chemotherapy for patients with unresectable, locally advanced diseases. Further randomization will be warranted to evaluate the true clinical benefit of the triplet regimen in patients with advanced pancreatic cancer. In recently years, molecular targeting agent either alone or in combination with chemotherapy or other targeting agents is the mainstream for hepatocellular carcinoma (HCC) studies in Taiwan, as well as the rest part of the world. However, the targeting therapy for advanced HCC in Taiwan was started with the thalidomide program in We firstly completed a phase I and pharmacokinetic study to show that severity of underlying cirrhosis does not affect the absorption and elimination of thalidomide in HCC patients, and the maximum tolerated dose and recommended dose of thalidomide for HCC patients was 300 and 200 mg/day, respectively. Further studies suggested that oral thalidomide has a potential to stabilizing the progression of advanced HCC (30-40% of disease stabilization rate with objective response in 5-10%) even in patients with severe underlying cirrhosis. Based on such observations, a placebo-controlled phase III trial has been taken to evaluate the true therapeutic effects of thalidomide in Child-Pugh s B/C HCC patients. In addition, to improve the surgical outcome of patients with curative resection of HCC, we had also conducted a randomized, phase III TCOG trial to evaluate whether the use of interferon-α, an anti-virus, anti-proliferative, and anti-angiogenic immunomodulator, could reduce or delay the recurrence and thus, to improve the survival in post-operative HCC patients or not. This is the largest adjuvant therapy trial for (target patients population: 268) post-operative HCC in the world. The preliminary results will be disclosed in the text. Keywords : Clinical trial, liver cancer, pancreatic cancer
2 L. T. Chen et al./ Proc JTJS (2007) ADENOCARCINOMA OF EXOCRINE PANCREAS Gemcitabine is the standard therapy for advanced pancreatic adenocarcinoma with modest anti-tumor efficacy, 6-11% of overall response rate and 5-6 months of overall survival time. We have made effort to improve the therapeutic efficacy by series of combination chemotherapy trials in advanced diseases. In the past decade years, we have firstly conducted a phase I/II trial of weekly gemcitabine (800 mg/m 2 ) plus 24-hr infusion of high-dose 5-FU/LV in advanced pancreatic cancer [1]. The treatment was given at day 1, 8 and 15 every 28 days, which demonstrated the regimen could achieve an overall and clinical benefit response rate of 22% and 46%, respectively; with median progression-free and overall survival of 4.1 and 6.9 months, respectively. The recommended dose of 5-FU for the combination was 2,000 mg/m 2. However, with the disclosure of ECOG 2297 trial, the combination of gemcitabine and 5-FU±LV became an unappealing regimen for further phase III study. Therefore, the combination of additional potentially active, non-cross resistant, and low-toxic cytotoxic agent seems to be a reasonable approach to further improve the therapeutic index of systemic chemotherapy for advanced pancreatic cancer. We had described an extremely excellent response of a metastatic pancreatic cancer to the combination of oxaliplatin to our gemcitabine-5-fu/lv regimen [2]. With such an observation, we started a phase I/II trial of biweekly gemcitabine (fixed rate infusion of 800 mg/m 2 ) followed by oxaliplatin and 48-hr infusion of 5-FU/LV (3000 and 300 mg/m 2, respectively), the GOFL regimen. The phase I study demonstrated that GOFL is a well-tolerated and moderate active (overall response rate of *Corresponding author: Li-Tzong Chen M.D., Ph.D. Tel: ext Fax: leochen@nhri.org.tw 33.3%), regimen for advanced pancreatic cancer. The recommended dose of oxaliplatin for phase II trial was 85 mg/m 2 [3]. In phase II study, 45 patients (median age: 57 years-old) were enrolled, 36 (80.0%) of them had metastatic diseases. A total of 342 cycles were delivered, with a median of 7 cycles (95% CI, cycles) per patient. Objective tumor response was achieved in 15, stable disease in 16, and progressive disease or unevaluable in 14. On intent-to-treat analysis, the overall response rate and disease-control rate was 33.3% (95% CI, %) and 68.9% (95% CI, %), respectively. Major grade 3/4 toxicities were neutropenia (33.3%, with 4.4% complicated with fever), nausea (15.6%), peripheral sensory neuropathy (15.6%), vomiting (8.9%) and diarrhea (8.9%). There was two treatment-related mortality. The median progression-free survival and overall survival was 4.7 months (95% CI, months) and 9.8 months (95% CI, months), respectively. The medial survivals of patients with metastatic and locally advanced disease were 7.8 months (95% CI, months) and 15.9 months (95% CI, months) respectively. The results showed that triplet regimen is not only feasible but also exhibits promising activity against advanced pancreatic cancer that deserves further exploration [4]. Management of unresectable, locally advanced pancreatic cancer patients remains controversial. Concurrent chemo-radiotherapy (CRT) is one of the most commonly used modality to treat locally advanced pancreatic cancer. However, systemic dissemination is the major cause of treatment failure, which may present even during or immediately after CRT. To treat undetectable metastases and to select patients who may potentially benefit from CRT, induction chemotherapy followed by CRT has recently become a favorable strategy for treating locally advanced pancreatic cancer. However, the efficacy of induction chemotherapy has been one of the major concerns for this multimodality approach. With the exciting results of GOFL regimen for patients with
3 62 L. T. Chen et al./ Proc JTJS (2007) Table 1. Okuda s stage-stratified overall survival in HCC patients who received thalidomide treatment Overall survival, months Okuda s Okuda et al.* Chen et al. 10 Stage Score Chemotherapy Untreated Thalidomide I (n=23) 8.3 (n=62) 7.6 (n=16) II (n=82) 2.0 (n=134) 2.6 (n=21) III (n=17) 0.7 (n=33) 3.9 (n=5) *, Okuda K, et al. Cancer 1985;56: locally advanced or metastatic pancreatic cancer, we have also initiated a phase II study of induction GOFL followed by CRT for locally advanced pancreatic cancer since In this study, patients who had responsive or stable diseases after 6 cycles (3 months) of induction GOFL would receive concurrent chemoradiotherapy (CRT) 3-4 weeks after the last dose of induction GOFL. Radiation was consisting of 5,040 cgy in 25 fractions along with weekly gemcitabine at dose of 400mg/m 2. Four weeks after completion of CRT, patients would be re-evaluated for surgical intervention. Inoperable patients would have further GOFL treatment until disease progression, the presence of unacceptable toxicity or patient's refusal. Among the 27 pts (13 F / 14 M, median age 61 years, range 29-80) who were enrolled into the first stage of the study, 24 (88%) and 9 (33%) of them had T3-4 and N2 disease, respectively. All 27 patients received induction chemotherapy and were evaluable for GO- FL-related toxicity. Thirteen patients off-studied after induction chemotherapy, due to disease progression in 10 and GOFL-related toxicity in 3. Among the 14 pts feasible for subsequent CRT, four refused CRT, thus only 10 pts received CRT and were evaluable for its toxicity. The most common grade 3/4 toxicities during induction GOFL were neutropenia (25.9%), nausea (33.3%), vomiting (25.9%), anorexia (18.5%) and anemia (11.1%). Grade 2 neuropathy occurred in 8 (29.7%). CRT was well-tolerated, and only one developed febrile neutropenia and 3 had grade 3/4 anemia. The results suggest GOFL followed by gemcitabine-based CRT is feasible in LAPC. Further patient accrual is still ongoing [5]. HEPATOCELLULAR CARCINOMA Therapy for Advanced Hepatocellular Carcinoma Hepatocellular carcinoma (HCC) is one of the most common cancers in the world and also the leading cause of cancer death of man in Taiwan. The median survival of symptomatic patients was less than 6 months. In recently years, molecular targeting agent either alone or in combination with chemotherapy or other targeting agents is the mainstream for hepatocellular carcinoma (HCC) studies in Taiwan, as well as the rest part of the world. However, the targeting therapy for advanced HCC in Taiwan was started with the thalidomide program in In a phase I study, we firstly determined the maximum tolerated dose and recommended dose of thalidomide in patients with HCC was 300 and 200 mg per day, respectively [6]. Further phase II study shown that thalidomide could have a tumor response rate of 7% and a disease control rate of 40% in advanced HCC [7]. Hemodynamic study with either dynamic contrast-enhanced MRI (DCE-MRI) or power Doppler sonography (PDS), both suggested thalidomide therapy was associated with significant reduction of tumor perfusion (measurement of the maximal enhancement, and the en-
4 L. T. Chen et al./ Proc JTJS (2007) hancement slope percentage in the first-pass study by DCE-MRI and tumor vascularity index by PDS) in responsive HCC, but not un-responsive ones [8,9]. Based on these findings, a concurrent chemoradiotherapy (CCRT) with thalidomide as radio-enhancer, with DCE-MRI assessment of perfusion changes before and 1 week after CCRT, is currently ongoing. In addition, we have recently demonstrated that tumor marker (alpha- fetoprotein, AFP) response can more accurately reflect the biological response of advanced HCC to thalidomide therapy than radiographic response [10]. Despite the low tumor response rate in earlier studies, thalidomide therapy may sometimes provide effective palliation for patients with far advanced HCC with symptomatic IVC/RA tumor thrombi and who are not candidates for alternative treatment options [11]. Subgroup analysis of our prior study showed that the survival of our HCC patients receiving thalidomide therapy was 7.6, 2.6 and 3.9 months for patients of Okuda stage I, II and III, respectively. The survival of corresponding group of patients who had not received any therapy in the original report of Okuda et al. was 8.3, 2.0 and 0.7 months, respectively (Table 1). Based on the results, we initiated a placebo-controlled, phase III study to evaluate the effects of thalidomide on the survival of patients with advanced HCC and poor liver reserve (Child- Pugh s B and C). Currently, 74 patients have been enrolled, and an interim analysis will be carried out after the accrual of 82 patients (amended according to the suggestion of Data Monitoring and Safety Committee of TCOG). The VGH-Cooperative Ward trial of transcatheter arterial chemoembolization (TACE) alone versus thalidomide plus TACE for HCC (initiated by Dr. Chao Yee) was early terminated because of poor patient accrual. Adjuvant Therapy in Patients with Curative Resection Early detection of asymptomatic, small HCC plus curative resection provides the best chance of long- term survival. Recently, several large series of hepatic resection in HCC have been published. Despite of the improvement of surgical techniques and postoperative care which make the operation mortality to decline below 10%, the 5-year survival rate of patients who underwent curative resection still less than 30-50%. Most of the patients had and died of intrahepatic recurrence. The high incidence of recurrence, lack of effective therapy after recurrence and subsequently poor outcome indicate the need for adjuvant therapy in post-operative HCC. A Taiwan Cooperative Oncology Group study, the T1297 is a randomization, phase III trial testing whether adjuvant interferon alfa-2b (IFNα-2b) can prevent or delay intrahepatic recurrence in post-operative viral-related hepatocellular carcinoma (HCC) or not. The preliminary data was firstly disclosed at the December 2004 TCOG Annual Meeting (in Conjunction with Asian-Pacific Gastrointestinal Tract Malignancies Symposium) and then presented in the Presidential Symposium of the 2005 AASLD Annual Meeting [12]. In this randomization, controlled study, patients with hepatitis B or C virus-related HCC that had curative resection (no radiographic evidence of vascular involvement, gross resection margin > 1 cm and negative cutting end in histology) were eligible. Patients were stratified by their viral status (HBsAg+ versus HBsAg-/anti-HCV+) and randomly allocated to adjuvant IFN-α2b treatment (53 weeks) or observation alone. Among the 264 eligible patients, with median follow-up of 41.8 [95% CI: ] months, 127 (48.1%) patients suffered disease recurrence (64 in IFN-α2b arm and 63 in observation arm), and 58 (22.0%) patients died (29 in IFN-α2b arm and 29 in observation arm). The 6-year overall survival (OS) rate was 68.4% in IFN-α2b arm and 72.1% in observation arm, (p=0.89, log-rank test); while the 6-year recurrence-free survival (RFS) rate was 42.3% and 45.6% (p=0.89, log-rank test), respectively. Among clinicopathological variables, only patients performance status, tumor size, and microvascular invasion were independent prognostic factors
5 64 L. T. Chen et al./ Proc JTJS (2007) for OS. Stepwise Cox s proportional hazard model analysis showed adjuvant IFN-a2b was an independent prognostic factor for better RFS [HR: (95% CI: ), p=0.032] and OS [HR: (95% CI: ), p=0.002] in HBsAg+ patients whose tumor equal or greater than 5 cm (n=68), but neither for those with tumor smaller than 5 cm (n=144) nor for HBsAg-/anti-HCV+ patients (n=52). We conclude that 53-week adjuvant IFN-α2b therapy did not improve the RFS and OS of post-operative viral-related HCC patients in this endemic area of HBV infection. Further study using less toxic, anti-hbv nucleotide/nucleoside as adjuvant setting in patients with low-risk of recurrence after curative resection of HBV-related HCC is currently ongoing. REFERENCES 1. Shiah HS, Cheng AL, Hsu C, et al. Phase I-II trial of weekly gemcitabine plus high-dose 5-fluorouracil and leucovorin in advanced pancreatic cancer. J Gastroenterol Hepatol 21: 531-6, Wu CW, Chen SC, Su YC, et al. Complete remission of metastatic pancreatic cancer with cardiac involvement after gemcitabine, oxaliplatin and 46-h infusion of 5-fluorouracil/leucovorin. J Gastroenterol Hepatol 19: 716-7, Ch ang HJ, Wang CC, Cheng AL, et al. Phase I study of biweekly gemcitabine, oxaliplatin and simplified 48-hr infusion of fluorouracil / leucovorin (GOFL) for advanced pancreatic cancer. J Gastroenterol Hepatol 21: 874-9, Chen LT, Ch'ang HJ, Huang CL, et al. Phase II study of biweekly gemcitabine followed by oxaliplatin and simplified 48-hr Infusion of 5- fluorouracil / leucovorin (GOFL) in advanced pancreatic cancer. Proceeding of ASCO GI Symposium, Chen LT, Ch'ang HJ, Huang CL, et al. Feasibility of gemcitabine-based chemoradiotherapy (CRT) after triplet chemotherapy (CT) for locally-advanced (LA) pancreatic cancer patients: Preliminary data from Taiwan Cooperative Oncology Group (TCOG) T1204 Study. Proceeding of ASCO GI Symposium, Shiah HS, Chao Y, Chen LT, et al. Phase I and pharmacokinetic study of oral thalidomide in patients with advanced hepatocellular carcinoma. Cancer Chemother Pharmacol 58: , Hsu C, Chen CN, Chen LT, et al. Low-dose thalidomide treatment for advanced hepatocellular carcinoma. Oncology 65: 242-9, Hsu C, Chen CN, Chen LT, et al. Use of power doppler sonography and circulating angiogenic factors to assess the anti-angiogenic effect of thalidomide in hepatocellular carcinoma. Radiology 235: , [SCI, 3/84, I.F.5.08]. 9. Wang J, Chen LT, Tsang YM, et al. Dynamic contrast-enhanced MRI analysis of perfusion changes in advanced hepatocellular carcinoma treated with an antiangiogenic agent: a preliminary study. Am J Roentgenol 183: 713-9, [SCI, 18/83, I.F. 2.47]. 10. Chen LT, Liu TW, Chao Y, et al. Alpha-fetoprotein response predicts survival benefits of thalidomide for advanced hepatocellular carcinom. Aliment Pharmacol Ther 22: , Chang JY, Ka WS, Chao TY, et al. Hepatocellular carcinoma with intra-atrial tumor thrombi A report of three cases responsive to thalidomide treatment and literature review. Oncology 67: 320-6, Chen LT, Chen MF, Li LA, et al. Randomized phase III study of adjuvant interferon alfa-2b in hepatocellular carcinoma with curative resection the Taiwan Cooperative Oncology Group (TCOG) T1297 study. Proceeding of 2005 AASLD Annual Meeting.
Adjuvant Treatment of Pancreatic Cancer in 2009: Where Are We? Highlights from the 45 th ASCO Annual Meeting. Orlando, FL, USA. May 29 - June 2, 2009
HIGHLIGHT ARTICLE - Slide Show Adjuvant Treatment of Pancreatic Cancer in 2009: Where Are We? Highlights from the 45 th ASCO Annual Meeting. Orlando, FL, USA. May 29 - June 2, 2009 Muhammad Wasif Saif
More informationMedicinae Doctoris. One university. Many futures.
Medicinae Doctoris The Before and The After: Can chemotherapy revise the trajectory of gastric and esophageal cancers? Dr. David Dawe MD, FRCPC Medical Oncologist Assistant Professor Disclosures None All
More informationThe 2010 Gastrointestinal Cancers Symposium Oral Abstract Session: Cancers of the Pancreas, Small Bowel and Hepatobilliary Tract
The 2010 Gastrointestinal Cancers Symposium : Cancers of the Pancreas, Small Bowel and Hepatobilliary Tract Abstract #131: Phase I study of MK 0646 (dalotuzumab), a humanized monoclonal antibody against
More informationAdjuvant Chemotherapy for Rectal Cancer: Are we making progress?
Adjuvant Chemotherapy for Rectal Cancer: Are we making progress? Hagen Kennecke, MD, MHA, FRCPC Division Of Medical Oncology British Columbia Cancer Agency October 25, 2008 Objectives Review milestones
More informationStudy Objective and Design
Randomized, Open Label, Multicenter, Phase II Trial of Transcatheter Arterial Chemoembolization (TACE) Therapy in Combination with Sorafenib as Compared With TACE Alone in Patients with Hepatocellular
More informationTargeted Therapies in Metastatic Colorectal Cancer: An Update
Targeted Therapies in Metastatic Colorectal Cancer: An Update ASCO 2007: Targeted Therapies in Metastatic Colorectal Cancer: An Update Bevacizumab is effective in combination with XELOX or FOLFOX-4 Bevacizumab
More informationVan Cutsem E et al. Proc ASCO 2009;Abstract LBA4509.
Efficacy Results from the ToGA Trial: A Phase III Study of Trastuzumab Added to Standard Chemotherapy in First-Line HER2- Positive Advanced Gastric Cancer Van Cutsem E et al. Proc ASCO 2009;Abstract LBA4509.
More informationHepatocellular Carcinoma HCC Updated November 2015 by: Dr. Mohammed Alghamdi (Medical Oncology Fellow, University of Calgary)
Hepatocellular Carcinoma HCC Updated November 2015 by: Dr. Mohammed Alghamdi (Medical Oncology Fellow, University of Calgary) Staff Reviewers: Dr. Yoo Joung Ko (Medical Oncologist, Sunnybrook Odette Cancer
More informationOverview. What s New in the Treatment of Pancreatic Cancer? Lots! Steven J. Cohen, M.D. Fox Chase Cancer Center September 17, 2013
What s New in the Treatment of Pancreatic Cancer? Lots! Steven J. Cohen, M.D. Fox Chase Cancer Center September 17, 2013 Overview Staging and Workup Resectable Disease Surgery Adjuvant therapy Locally
More informationCelsion Symposium New Paradigms in HCC Staging: HKLC vs. BCLC Staging
Celsion Symposium New Paradigms in HCC Staging: HKLC vs. BCLC Staging Ronnie T.P. Poon, MBBS, MS, PhD Chair Professor of Hepatobiliary and Pancreatic Surgery Chief of Hepatobiliary and Pancreatic Surgery
More informationChemotherapy of colon cancers
Chemotherapy of colon cancers Stage distribution Stage I : 15% T 1,2 NO Stage IV: 20 25% M+ Stage II : 20 30% T3,4 NO Stage III N+: 30 40% clinical stages I, II, or III colon cancer are at risk for having
More informationCisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer. Valle J et al. N Engl J Med 2010;362(14):
Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer Valle J et al. N Engl J Med 2010;362(14):1273-81. Introduction > Biliary tract cancers (BTC: cholangiocarcinoma, gall bladder cancer,
More informationSorafenib for Egyptian patients with advanced hepatocellular carcinoma; single center experience
Journal of the Egyptian National Cancer Institute (2014) 26, 9 13 Cairo University Journal of the Egyptian National Cancer Institute www.nci.cu.adu.eg www.sciencedirect.com Original article Sorafenib for
More informationGASTRIC & PANCREATIC CANCER
GASTRIC & PANCREATIC CANCER ASCO HIGHLIGHTS 2005 Fadi Sami Farhat, MD Head of Hematology Oncology Division Hammoud Hospital University Medical Center Saida Lebanon Tel: +961 3 753 155 E-Mail: drfadi@drfadi.org
More informationESMO 2017, Madrid, Spain Dr. Loredana Vecchione Charite Comprehensive Cancer Center, Berlin HIGHLIGHTS ON CANCERS OF THE UPPER GI TRACT
ESMO 2017, Madrid, Spain Dr. Loredana Vecchione Charite Comprehensive Cancer Center, Berlin HIGHLIGHTS ON CANCERS OF THE UPPER GI TRACT DOCETAXEL, OXALIPLATIN AND FLUOROURACIL/LEUCOVORIN (FLOT) FOR RESECTABLE
More informationIl treatment plan nella terapia sistemica dell epatocarcinoma
Il treatment plan nella terapia sistemica dell epatocarcinoma M. Iavarone, MD PhD CRC A.M. e A. Migliavacca Center for the Study of Liver Disease Division of Gastroenterology and Hepatology Fondazione
More informationChemotherapy-induced HBV reactivation in cancer patients
Chemotherapy-induced HBV reactivation in cancer patients On behalf of Taiwan Cooperative Oncology Group (TCOG) HBV reactivation in lymphoma patients: What we have known HBV reactivation and hepatitis flares
More informationPrimary Endpoint The primary endpoint is overall survival, measured as the time in weeks from randomization to date of death due to any cause.
CASE STUDY Randomized, Double-Blind, Phase III Trial of NES-822 plus AMO-1002 vs. AMO-1002 alone as first-line therapy in patients with advanced pancreatic cancer This is a multicenter, randomized Phase
More informationA phase II study of weekly paclitaxel and cisplatin followed by radical hysterectomy in stages IB2 and IIA2 cervical cancer AGOG14-001/TGOG1008
A phase II study of weekly paclitaxel and cisplatin followed by radical hysterectomy in stages IB2 and IIA2 cervical cancer AGOG14-001/TGOG1008 NCT02432365 Chyong-Huey Lai, MD On behalf of Principal investigator
More informationReference No: Author(s) Approval date: 12/05/16. Committee. June Operational Date: Review:
Reference No: Title: Author(s) Systemic Anti-Cancer Therapy (SACT) Guidelines for Biliary Tract Cancer (BTC) Dr Colin Purcell, Consultant Medical Oncologist on behalf of the GI Oncologists Group, Cancer
More informationHEPATOCELLULAR CARCINOMA: SCREENING, DIAGNOSIS, AND TREATMENT
HEPATOCELLULAR CARCINOMA: SCREENING, DIAGNOSIS, AND TREATMENT INTRODUCTION: Hepatocellular carcinoma (HCC): Fifth most common cancer worldwide Third most common cause of cancer mortality In Egypt: 2.3%
More informationEvolving Paradigms in HER2+ MBC: Strategies for Individualizing Therapy with Available Agents
Evolving Paradigms in HER2+ MBC: Strategies for Individualizing Therapy with Available Agents Kimberly L. Blackwell MD Professor Department of Medicine and Radiation Oncology Duke University Medical Center
More informationLiver and Biliary Tract Cancers Critical Review
Liver and Biliary Tract Cancers Critical Review Lorenza Rimassa Oncologia Medica e Ematologia Humanitas Cancer Center Humanitas Research Hospital Rozzano (Milano) Critical review Oral presentations Melero
More informationJuly, ArQule, Inc.
July, 2012 Safe Harbor This presentation and other statements by ArQule may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act with respect to clinical
More informationWhere are we with radiotherapy for biliary tract cancers?
Where are we with radiotherapy for biliary tract cancers? Professor Maria A. Hawkins Associate Professor in Clinical Oncology MRC Group Leader/Honorary Consultant Clinical Oncologist CRUK MRC Oxford Institute
More informationEmbolotherapy for Cholangiocarcinoma: 2016 Update
Embolotherapy for Cholangiocarcinoma: 2016 Update Igor Lobko,MD Chief, Division Vascular and Interventional Radiology Long Island Jewish Medical Center GEST 2016 Igor Lobko, M.D. No relevant financial
More informationCetuximab plus 5-FU/FA/oxaliplatin (FOLFOX-4) in the first-line treatment of metastatic colorectal cancer: a large-scale Phase II study (OPUS)
Cetuximab plus 5-FU/FA/oxaliplatin (FOLFOX-4) in the first-line treatment of metastatic colorectal cancer: a large-scale Phase II study (OPUS) C Bokemeyer, E Staroslawska, A Makhson, I Bondarenko, JT Hartmann,
More informationLung Cancer Non-small Cell Local, Regional, Small Cell, Other Thoracic Cancers: The Question Isn t Can We, but Should We
Lung Cancer Non-small Cell Local, Regional, Small Cell, Other Thoracic Cancers: The Question Isn t Can We, but Should We Edward Garon, MD, MS Associate Professor Director- Thoracic Oncology Program David
More informationA) PUBLIC HEALTH B) PRESENTATION & DIAGNOSIS
Hepatocellular Carcinoma HCC Updated November 2015 by: Dr. Mohammed Alghamdi (Medical Oncology Fellow, University of Calgary), April 2017 by Dr. Jenny Ko (Medical Oncologist, Abbotsford Centre, BC Cancer
More informationTGFβR1 Kinase Inhibitor
TGFβR1 Kinase Inhibitor Galunisertib, LY2157299 H 2 0 Prud homme GJ 1 ; Flavell RA, et al 2 Drug Discovery Platform: Cancer Angiogenesis and Tumor Microenvironment/Immuno-Oncology A Phase 1b/2 Dose-Escalation
More informationNasopharyngeal Cancer:Role of Chemotherapy
Nasopharyngeal Cancer:Role of Chemotherapy PANAGIOTIS KATSAOUNIS Medical Oncologist IASO GENERAL HOSPITAL Athens, 16/9/2017 2 nd Hellenic Multidisciplinary Conference on Head and Neck Cancer INTRODUCTION
More information蕾莎瓦 Nexavar 臨床試驗資料 (HCC 肝細胞癌 )
蕾莎瓦 Nexavar 臨床試驗資料 (HCC 肝細胞癌 ) 1 Sorafenib Improves Survival in Hepatocellular Carcinoma: Results of a Phase III Randomized, -Controlled Trial Josep M. Llovet, Sergio Ricci, Vincenzo Mazzaferro, Philip
More informationReference No: Author(s) 12/05/16. Approval date: committee. June Operational Date: Review:
Reference No: Title: Author(s) Systemic Anti-Cancer Therapy (SACT) Guidelines for Pancreatic Adenocarcinoma Dr Colin Purcell, Consultant Medical Oncologist & on behalf of the GI Oncologists Group, Cancer
More informationPresentation by Dr. Thomas Yau on behalf of his co-authors
4078 First presented at the American Society of Clinical Oncology (ASCO) 2016 Annual Meeting, Chicago, Illinois, USA, June 3-7, 2016. Reused with permission from the American Society of Clinical Oncology
More informationAdvances in Systemic Therapy Hepatocellular Carcinoma (HCC) Dr ZEE Ying Kiat HASLD Conference Ho Chi Minh City, 18 December 2016
Advances in Systemic Therapy for Hepatocellular Carcinoma (HCC) Dr ZEE Ying Kiat HASLD Conference Ho Chi Minh City, 18 December 2016 Scope Background Staging and treatment strategies Current systemic therapy
More informationTGFβR1 Kinase Inhibitor
TGFβR1 Kinase Inhibitor Galunisertib, LY2157299 H 2 0 Derived from Prud homme GJ 1 ; Flavell RA, et al. 2 Drug Discovery Platform: Cancer Angiogenesis and Tumor Microenvironment/Immuno-Oncology A Phase
More informationClinical Study Gemcitabine Plus Carboplatin in Patients with Advanced Hepatocellular Carcinoma: Results of a Phase II Study
International Scholarly Research Network ISRN Oncology Volume 2012, Article ID 420931, 5 pages doi:10.5402/2012/420931 Clinical Study Gemcitabine Plus Carboplatin in Patients with Advanced Hepatocellular
More informationHepatobiliary Malignancies Retrospective Study at Truman Medical Center
Hepatobiliary Malignancies 206-207 Retrospective Study at Truman Medical Center Brandon Weckbaugh MD, Prarthana Patel & Sheshadri Madhusudhana MD Introduction: Hepatobiliary malignancies are cancers which
More informationCancer Cell Research 14 (2017)
Available at http:// www.cancercellresearch.org ISSN 2161-2609 Efficacy and safety of bevacizumab for patients with advanced non-small cell lung cancer Ping Xu, Hongmei Li*, Xiaoyan Zhang Department of
More informationEdith A. Perez, Ahmad Awada, Joyce O Shaughnessy, Hope Rugo, Chris Twelves, Seock-Ah Im, Carol Zhao, Ute Hoch, Alison L. Hannah, Javier Cortes
BEACON: A Phase 3 Open-label, Randomized, Multicenter Study of Etirinotecan Pegol (EP) versus Treatment of Physician s Choice (TPC) in Patients With Locally Recurrent or Metastatic Breast Cancer Previously
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the clinical
More informationIrinotecan (CPT-11) in Patients with Advanced Colon Carcinoma Relapsing after 5-Fluorouracil-Leucovorin Combination
Clinical Report Chemotherapy 2002;48:94 99 Irinotecan (CPT-11) in Patients with Advanced Colon Carcinoma Relapsing after 5-Fluorouracil-Leucovorin Combination N.B. Tsavaris a A. Polyzos b K. Gennatas c
More informationTargeted Agents as Maintenance Therapy. Karen Kelly, MD Professor of Medicine UC Davis Cancer Center
Targeted Agents as Maintenance Therapy Karen Kelly, MD Professor of Medicine UC Davis Cancer Center Disclosures Genentech Advisory Board Maintenance Therapy Defined Treatment Non-Progressing Patients Drug
More informationHEPATOCELLULAR CARCINOMA N. A.OTHIENO ABINYA
HEPATOCELLULAR CARCINOMA N. A.OTHIENO ABINYA - One of the most common solid organ tumours worldwide. - A public health problem in parts of Asia and subsaharan Africa, with incidence upto 50/100,000 population/year.
More informationDocetaxel. Class: Antineoplastic agent, Antimicrotubular, Taxane derivative.
Docetaxel Class: Antineoplastic agent, Antimicrotubular, Taxane derivative. Indications: -Breast cancer: -Non small cell lung cancer -Prostate cancer -Gastric adenocarcinoma _Head and neck cancer Unlabeled
More informationIndex. Note: Page numbers of article titles are in boldface type.
Index Note: Page numbers of article titles are in boldface type. A Abdominal drainage, after hepatic resection, 159 160 Ablation, radiofrequency, for hepatocellular carcinoma, 160 161 Adenocarcinoma, pancreatic.
More informationChemotherapy of Breast Cancer
Japan - Taiwan Joint Symposium on Medical Oncology Session 7 Breast cancer journal homepage:www.cos.org.tw/web/index.asp Chemotherapy of Breast Cancer Mei-Ching Liu Department of Medicine, Koo Foundation
More informationRESEARCH ARTICLE. Validation of The Hong Kong Liver Cancer Staging System in Patients with Hepatocellular Carcinoma after Curative Intent Treatment
DOI:10.22034/APJCP.2017.18.6.1697 RESEARCH ARTICLE Validation of The Hong Kong Liver Cancer Staging System in Patients with Hepatocellular Carcinoma after Curative Intent Treatment Alan Chuncharunee 1,
More informationNexavar in advanced HCC: a paradigm shift in clinical practice
Nexavar in advanced HCC: a paradigm shift in clinical practice Tim Greten Hanover Medical School, Germany Histopathological progression and molecular features of HCC Chronic liver disease Liver cirrhosis
More informationImmunotherapy in the Adjuvant Setting for Melanoma: What You Need to Know
Immunotherapy in the Adjuvant Setting for Melanoma: What You Need to Know Jeffrey Weber, MD, PhD Laura and Isaac Perlmutter Cancer Center NYU Langone Medical Center New York, New York What Is the Current
More informationSPECIAL AUTHORIZATION REQUEST FOR COVERAGE OF HIGH COST CANCER DRUGS
SPECIAL AUTHORIZATION REQUEST FOR COVERAGE OF HIGH COST CANCER DRUGS (Filgrastim, Capecitabine, Imatinib, Dasatinib, Erolotinib, Sunitinib, Pazopanib, Fludarabine, Sorafenib, Crizotinib, Tretinoin, Nilotinib,
More informationAdvances in gastric cancer: How to approach localised disease?
Advances in gastric cancer: How to approach localised disease? Andrés Cervantes Professor of Medicine Classical approach to localised gastric cancer Surgical resection Pathology assessment and estimation
More informationManagement of HepatoCellular Carcinoma
9th Symposium GIC St Louis - 2010 Management of HepatoCellular Carcinoma Overview Pierre A. Clavien, MD, PhD Department of Surgery University Hospital Zurich Zurich, Switzerland Hepatocellular carcinoma
More informationNon-small Cell Lung Cancer: Multidisciplinary Role: Role of Medical Oncologist
Non-small Cell Lung Cancer: Multidisciplinary Role: Role of Medical Oncologist Vichien Srimuninnimit, MD. Medical Oncology Division Faculty of Medicine, Siriraj Hospital Outline Resectable NSCLC stage
More informationPredictive Factors of Outcome and Tumor Response to Systemic Chemotherapy in Patients with Metastatic Hepatocellular Carcinoma
Predictive Factors of Outcome and Tumor Response to Systemic Chemotherapy in Patients with Metastatic Hepatocellular Carcinoma Masafumi Ikeda 1,2, Takuji Okusaka 1, Hideki Ueno 1, Chigusa Morizane 1, Yasushi
More informationSurgical Management of Advanced Stage Colon Cancer. Nathan Huber, MD 6/11/14
Surgical Management of Advanced Stage Colon Cancer Nathan Huber, MD 6/11/14 Colon Cancer Overview Approximately 50,000 attributable deaths per year Colorectal cancer is the 3 rd most common cause of cancer-related
More informationSurgical resection improves survival in pancreatic cancer patients without vascular invasion- a population based study
Original article Annals of Gastroenterology (2013) 26, 346-352 Surgical resection improves survival in pancreatic cancer patients without vascular invasion- a population based study Subhankar Chakraborty
More informationSTUDY FINDINGS PRESENTED ON TAXOTERE REGIMENS IN HEAD AND NECK, LUNG AND BREAST CANCER
Contact: Anne Bancillon + 33 (0)6 70 93 75 28 STUDY FINDINGS PRESENTED ON TAXOTERE REGIMENS IN HEAD AND NECK, LUNG AND BREAST CANCER Key results of 42 nd annual meeting of the American Society of Clinical
More informationHCC: Is it an oncological disease? - No
June 13-15, 2013 Berlin, Germany Prof. Oren Shibolet Head of the Liver Unit, Department of Gastroenterology Tel-Aviv Sourasky Medical Center and Tel-Aviv University HCC: Is it an oncological disease? -
More informationADVANCED COLORECTAL CANCER: UNRESECTABLE OR BORDERLINE RESECTABLE (GROUP 1) CHEMOTHERAPY +/- TARGETED AGENTS. Andrés Cervantes. Professor of Medicine
ADVANCED COLORECTAL CANCER: UNRESECTABLE OR BORDERLINE RESECTABLE (GROUP 1) CHEMOTHERAPY +/- TARGETED AGENTS Andrés Cervantes Professor of Medicine 1995 One option Advances in the treatment of mcrc 2000
More informationRADIATION THERAPY WITH ONCE-WEEKLY GEMCITABINE IN PANCREATIC CANCER: CURRENT STATUS OF CLINICAL TRIALS
doi:10.1016/s0360-3016(03)00449-8 Int. J. Radiation Oncology Biol. Phys., Vol. 56, No. 4, Supplement, pp. 10 15, 2003 Copyright 2003 Elsevier Inc. Printed in the USA. All rights reserved 0360-3016/03/$
More informationpan-canadian Oncology Drug Review Final Clinical Guidance Report Nab-Paclitaxel (Abraxane) for Pancreatic Cancer September 23, 2014
pan-canadian Oncology Drug Review Final Clinical Guidance Report Nab-Paclitaxel (Abraxane) for Pancreatic Cancer September 23, 2014 DISCLAIMER Not a Substitute for Professional Advice This report is primarily
More informationSorafenib for Advanced Hepatocellular Carcinoma
CED-SOS Advice Report 7 ARCHIVED 2012 Sorafenib for Advanced Hepatocellular Carcinoma J. Knox, R. Cosby, K. Chan, and M. Sherman A Quality Initiative of the Program in Evidence-Based Care (PEBC), Cancer
More informationAdjuvant therapies for large bowel cancer Wasantha Rathnayake, MD
LEADING ARTICLE Adjuvant therapies for large bowel cancer Wasantha Rathnayake, MD Consultant Clinical Oncologist, National Cancer Institute, Maharagama, Sri Lanka. Key words: Large bowel; Cancer; Adjuvant
More informationHepatobiliary and Pancreatic Malignancies
Hepatobiliary and Pancreatic Malignancies Gareth Eeson MD MSc FRCSC Surgical Oncologist and General Surgeon Kelowna General Hospital Interior Health Consultant, Surgical Oncology BC Cancer Agency Centre
More informationPancreatic Cancer Where are we?
Pancreatic Cancer Treatment Approaches & Options Pancreatic Cancer Action Network OUMC 9/22/2016 Russell G. Postier, MD Pancreatic Cancer Where are we? Estimated 2016 data 3% of cancer cases 7% of cancer
More informationNasopharyngeal Cancer/Multimodality Treatment
Nasopharyngeal Cancer/Multimodality Treatment PANAGIOTIS KATSAOUNIS Medical Oncologist IASO GENERAL HOSPITAL Athens, 22/10/2016 1 st Hellenic Multidisciplinary Conference on Head and Neck Cancer INTRODUCTION
More informationRecent advances in the management of metastatic breast cancer in older adults
Recent advances in the management of metastatic breast cancer in older adults Laura Biganzoli Medical Oncology Dept New Hospital of Prato Istituto Toscano Tumori Italy Important recent advances in the
More informationBendamustine is Effective Therapy in Patients with Rituximab-Refractory, Indolent B-Cell Non-Hodgkin Lymphoma
Bendamustine is Effective Therapy in Patients with Rituximab-Refractory, Indolent B-Cell Non-Hodgkin Lymphoma Kahl BS et al. Cancer 2010;116(1):106-14. Introduction > Bendamustine is a novel alkylating
More informationAdjuvant Chemotherapy
State-of-the-art: standard of care for resectable NSCLC Adjuvant Chemotherapy JY DOUILLARD MD PhD Professor of Medical Oncology Integrated Centers of Oncology R Gauducheau University of Nantes France Adjuvant
More informationTumor incidence varies significantly, depending on geographical location.
Hepatocellular carcinoma is the 5 th most common malignancy worldwide with male-to-female ratio 5:1 in Asia 2:1 in the United States Tumor incidence varies significantly, depending on geographical location.
More informationNew Targeted Agents Demonstrate Greater Efficacy and Tolerability in the Treatment of HER2-positive Breast Cancer
New Evidence reports on presentations given at ASCO 2012 New Targeted Agents Demonstrate Greater Efficacy and Tolerability in the Treatment of HER2-positive Breast Cancer Presentations at ASCO 2012 Breast
More informationSurveillance for Hepatocellular Carcinoma
Surveillance for Hepatocellular Carcinoma Marion G. Peters, MD John V. Carbone, MD, Endowed Chair Professor of Medicine Chief of Hepatology Research University of California San Francisco Recorded on April
More informationPancreatic Ca Update
Pancreatic Ca Update Caio Max S. Rocha Lima, M.D. M. Robert Cooper Professor in Medical Oncology Co-leader GI Oncology and Co-leader Phase I Program Wake Forest School of Medicine E-mail:crochali@wakehealth.edu
More informationAdjuvant therapy in pancreatic cancer Monotherapy for whom? JL VAN LAETHEM, MD,PhD
Adjuvant therapy in pancreatic cancer Monotherapy for whom? JL VAN LAETHEM, MD,PhD Efficacy Parameters in adjuvant monochemotherapy Randomized studies in resectable PDAC Regimen DFS HR (p) OS HR (p) 5-yr-OS
More informationIntended for use by Clinicians and Health Care Providers involved in the Management or Referral of adult patients with pancreatic
Intended for use by Clinicians and Health Care Providers involved in the Management or Referral of adult patients with pancreatic cancer Section AA Cancer Centre Referrals In the absence of metastatic
More informationThe legally binding text is the original French version
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 29 November 2006 TAXOTERE 20 mg, concentrate and solvent for infusion in single-dose vials of 7 ml, individually packed
More informationPractice changing studies in lung cancer 2017
1 Practice changing studies in lung cancer 2017 Rolf Stahel University Hospital of Zürich Cape Town, February 16, 2018 DISCLOSURE OF INTEREST Consultant or Advisory Role in the last two years I have received
More informationHepatocellular carcinoma in Sri Lanka - where do we stand?
SCIENTIFIC ARTICLE Hepatocellular carcinoma in Sri Lanka - where do we stand? R.C. Siriwardana 1, C.A.H. Liyanage 1, M.B. Gunethileke 2 1. Specialist Gastrointestinal and Hepatobilliary Surgeon, Senior
More informationCornerstones of Hepatitis B: Past, Present and Future
Cornerstones of Hepatitis B: Past, Present and Future Professor Man-Fung Yuen Queen Mary Hospital The University of Hong Kong Hong Kong 1 Outline Past Natural history studies Development of HBV-related
More informationCase 1 Metastatic Pancreatic Adenocarcinoma: What Therapy Should I Select First?
Case 1 Metastatic Pancreatic Adenocarcinoma: What Therapy Should I Select First? Marc Peeters, MD, PhD Head of the Oncology Department Antwerp University Hospital Antwerp, Belgium marc.peeters@uza.be 71-year-old
More informationHepatocellular Carcinoma. Markus Heim Basel
Hepatocellular Carcinoma Markus Heim Basel Outline 1. Epidemiology 2. Surveillance 3. (Diagnosis) 4. Staging 5. Treatment Epidemiology of HCC Worldwide, liver cancer is the sixth most common cancer (749
More informationOUR EXPERIENCES WITH ERLOTINIB IN SECOND AND THIRD LINE TREATMENT PATIENTS WITH ADVANCED STAGE IIIB/ IV NON-SMALL CELL LUNG CANCER
& OUR EXPERIENCES WITH ERLOTINIB IN SECOND AND THIRD LINE TREATMENT PATIENTS WITH ADVANCED STAGE IIIB/ IV NON-SMALL CELL LUNG CANCER Interim Data Report of TRUST study on patients from Bosnia and Herzegovina
More informationAdjuvant Therapy in Locally Advanced Head and Neck Cancer. Ezra EW Cohen University of Chicago. Financial Support
Adjuvant Therapy in Locally Advanced Head and Neck Cancer Ezra EW Cohen University of Chicago Financial Support This program is made possible by an educational grant from Eli Lilly Oncology, who had no
More informationTHE ROLE OF RADIATION THERAPY IN MANAGEMENT OF PANCREATIC ADENOCARCINOMA. TIMUR MITIN, MD, PhD
THE ROLE OF RADIATION THERAPY IN MANAGEMENT OF PANCREATIC ADENOCARCINOMA TIMUR MITIN, MD, PhD RESECTABLE DISEASE MANAGEMENT: RESECTABLE DISEASE Resection offers the only possibility of long term survival
More informationDr Roopinder Gillmore July 2017
Dr Roopinder Gillmore July 2017 Resectable Borderline / locally advanced Metastatic 15-20% 15-20% 60-70% 22-28 months 9-15 months 6-12 months Does the patient have resectable disease?? Definitely not
More informationCombined Modality Therapy State of the Art. Everett E. Vokes The University of Chicago
Combined Modality Therapy State of the Art Everett E. Vokes The University of Chicago What we Know Some patients are cured (20%) Induction and concurrent chemoradiotherapy are each superior to radiotherapy
More informationLiver resection for HCC
8 th LIVER INTEREST GROUP Annual Meeting Cape Town 2017 Liver resection for HCC Jose Ramos University of the Witwatersrand Donald Gordon Medical Centre The liver is almost unique in that treatment of the
More informationSan Antonio Breast Cancer Symposium 2010 Highlights Radiotherapy
San Antonio Breast Cancer Symposium 2010 Highlights Radiotherapy Kathleen C. Horst, M.D. Assistant Professor Department of Radiation Oncology Stanford University The Optimal SEquencing of Adjuvant Chemotherapy
More informationTiming of targeted therapy in patients with low volume mrcc. Eli Rosenbaum Davidoff Cancer Center Beilinson Hospital
1 Timing of targeted therapy in patients with low volume mrcc Eli Rosenbaum Davidoff Cancer Center Beilinson Hospital 2 Wont be discussing: Symptomatic patients High volume disease Rapidly growing metastases
More informationPancreatic Adenocarcinoma
Pancreatic Adenocarcinoma AProf Lara Lipton 28 April 2018 Percentage alive 5 years after diagnosis for men and women Epidemiology 6% of cancer related deaths worldwide 4 th highest cause of cancer death
More informationWhich Treatment Approach is Most Appropriate for Primary Therapy of Gastric Cancer: Neoadjuvant Chemotherapy
Which Treatment Approach is Most Appropriate for Primary Therapy of Gastric Cancer: Neoadjuvant Chemotherapy Joseph Chao, M.D. Assistant Clinical Professor Department of Medical Oncology & Therapeutics
More informationCase Conference. Craig Morgenthal Department of Surgery Long Island College Hospital
Case Conference Craig Morgenthal Department of Surgery Long Island College Hospital Neoadjuvant versus Adjuvant Radiation Therapy in Rectal Carcinoma Epidemiology American Cancer Society statistics for
More informationTHORACIC MALIGNANCIES
THORACIC MALIGNANCIES Summary for Malignant Malignancies. Lung Ca 1 Lung Cancer Non-Small Cell Lung Cancer Diagnostic Evaluation for Non-Small Lung Cancer 1. History and Physical examination. 2. CBCDE,
More informationHepatocellular Carcinoma Surveillance
Amit G. Singal, MD, MS Hepatocellular Carcinoma Surveillance Postgraduate Course: Challenges in Management of Common Liver Diseases 308 1 Patient Case 69 year-old otherwise healthy male with compensated
More informationFirst-line therapy for unresectable HCC:
ESMO GI Cancer Preceptorship 15 November 2017 Singapore First-line therapy for unresectable HCC: an oncologist s viewpoint Chiun Hsu, MD, PhD G raduate I n stitute of Oncology, National Taiwan Univers
More informationScreening for HCCwho,
Screening for HCCwho, how and how often? Catherine Stedman Associate Professor of Medicine, University of Otago, Christchurch Gastroenterology Department, Christchurch Hospital HCC Global Epidemiology
More informationConcurrent Chemoradiation of Patients with Inoperable
Med. J. Cairo Univ., VoL 81, No. 2, March: 29-34, 2013 www.medicaljournalofcairouniversity.com Concurrent Chemoradiation of Patients with Inoperable Non-Metastatic Pancreatic Cancer MOHAMED S. ELZAHI,
More informationEmerging Role of Immunotherapy in Head and Neck Cancer
Emerging Role of Immunotherapy in Head and Neck Cancer Jared Weiss, MD Associate Professor of Medicine and Section Chief of Thoracic and Head/Neck Oncology UNC Lineberger Comprehensive Cancer Center Copyright
More informationRETHINKING OUR APPROACH TO INTERMEDIATE-SIZE HCC
SATELLITE SYMPOSIUM Emerging Horizons in HCC: From Palliation to Cure RETHINKING OUR APPROACH TO INTERMEDIATE-SIZE HCC Professor Riccardo Lencioni, MD, FSIR, EBIR University of Pisa School of Medicine,
More information